文献速递淋巴瘤白血病浆细胞疾病

嵌合抗原受体T细胞治疗血液系统恶性肿瘤:从基础与转化研究到临床实践的见解

Chimeric antigen receptor T-cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice.
PubMed 文献 · Br J Haematol · 2024-09-11

本综述总结自体嵌合抗原受体(CAR)T细胞治疗淋巴系统恶性肿瘤的临床、转化与基础研究证据。CD19-CAR T细胞已获批用于B细胞淋巴瘤和急性白血病,B细胞成熟抗原(BCMA)-CAR T细胞用于多发性骨髓瘤。早期临床试验长期随访显示可获得长期缓解并可能治愈,且显著长期副作用发生率低、应答者生活质量快速改善。

要点

  • CD19-CAR T细胞已获批用于B细胞淋巴瘤和急性白血病,BCMA-CAR T细胞用于多发性骨髓瘤。
  • 早期临床试验长期随访显示长期缓解可能,提示治愈,且显著长期副作用发生率低。
  • 部分患者仍治疗失败或最终复发,需改进CAR T细胞疗法并理解疗效决定因素。

核心结论

  • 自体CAR T细胞疗法革新了淋巴系统恶性肿瘤的治疗,早期试验长期随访显示长期缓解可能提示治愈。
  • 部分患者仍治疗失败或复发,需改进CAR T细胞并理解疗效决定因素以最大化良好结局。
  • 下一代CAR T细胞将更有效,当前可用CAR T细胞已存在优化机会。

研究设计与样本

  • 综述文章,总结临床、转化和基础研究的当前证据,为临床医生提供理解和应用CAR T细胞的见解。

主要发现

  • CD19-CAR T细胞获批用于B细胞淋巴瘤和急性白血病,BCMA-CAR T细胞用于多发性骨髓瘤。
  • 早期临床试验长期随访显示长期缓解可能,提示治愈,与显著长期副作用发生率低及应答者生活质量快速改善相关。
  • 其他免疫疗法需延长治疗或携带损害生活质量的长期副作用风险。
  • 部分患者仍治疗失败或最终复发。

临床怎么用

  • 综述旨在为临床医生提供见解以增强对CAR T细胞的理解和使用,当前可用CAR T细胞已存在优化机会。

局限性

  • 部分患者仍治疗失败或最终复发,需改进CAR T细胞疗法并更好理解疗效决定因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autologous chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of lymphoid malignancies, leading to the approval of CD19-CAR T cells for B-cell lymphomas and acute leukaemia, and more recently, B-cell maturation antigen-CAR T cells for multiple myeloma. The long-term follow-up of patients treated in the early clinical trials demonstrates the possibility for long-term remission, suggesting a cure. This is associated with a low incidence of significant long-term side effects and a rapid improvement in the quality of life for responders. In contrast, other types of immunotherapies require prolonged treatments or carry the risk of long-term side effects impairing the quality of life. Despite impressive results, some patients still experience treatment failure or ultimately relapse, underscoring the imperative to improve CAR T-cell therapies and gain a better understanding of their determinants of efficacy to maximize positive outcomes. While the next-generation of CAR T cells will undoubtingly be more potent, there are already opportunities for optimization when utilizing the currently available CAR T cells. This review article aims to summarize the current evidence from clinical, translational and fundamental research, providing clinicians with insights to enhance their understanding and use of CAR T cells.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Grégoire C, Coutinho de Oliveira B, Caimi PF, et al. Chimeric antigen receptor T-cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice. Br J Haematol. 2024. PMID: 39262037. doi:10.1111/bjh.19751

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。